Cantor Fitzgerald Reiterates Overweight on Krystal Biotech, Maintains $160 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Krystal Biotech (NASDAQ:KRYS) and maintained a $160 price target.
November 07, 2023 | 4:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Krystal Biotech and maintained a $160 price target, which could positively impact the stock.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, Cantor Fitzgerald's reiteration of an Overweight rating and a $160 price target for Krystal Biotech indicates a positive outlook for the company, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100